资料显示，中牧实业股份有限公司位于北京市丰台区南四环西路188号八区16-19号楼，成立日期1998年 12月25日，上市日期1999年1月7日，公司主营业务涉及动物保健品,包括畜禽用疫苗、诊断液、兽药等 几大类。动物营养品:包括饲料原料、饲料添加剂、预混合饲料及大宗饲料原料的进出口贸易。主营业 务收入构成为：化药35.78%，贸易27.87%，饲料19.21%，生物制品16.10%，其他1.04%。 中牧股份所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：禽流感药物、兽 药、年报预增、宠物经济、病毒防治等。 2月24日，中牧股份盘中上涨2.09%，截至13:43，报7.83元/股，成交6372.50万元，换手率0.80%，总市 值79.96亿元。 资金流向方面，主力资金净流入208.71万元，特大单买入755.45万元，占比11.85%，卖出151.59万元， 占比2.38%；大单买入1138.46万元，占比17.87%，卖出1533.62万元，占比24.07%。 中牧股份今年以来股价跌0.51%，近5个交易日跌1.26%，近20日跌7.77%，近60日跌0.13%。 机构持仓方面，截止 ...

Core Viewpoint - Yiling Pharmaceutical's stock price has shown fluctuations, with a recent decline of 2.02% and a year-to-date increase of 5.27%, indicating mixed market sentiment towards the company [1]. Group 1: Stock Performance - As of January 29, Yiling Pharmaceutical's stock price was 17.97 yuan per share, with a market capitalization of 30.023 billion yuan [1]. - The stock has experienced a 1.96% decline over the last five trading days, but a 5.09% increase over the last 20 days [1]. - The company has seen a net outflow of 619.48 million yuan in principal funds, with significant selling pressure from large orders [1]. Group 2: Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 1 billion yuan, reflecting an 80.33% increase year-on-year [2]. - Cumulatively, the company has distributed 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed over the past three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 10.22% to 152,700, while the average number of circulating shares per person increased by 11.38% to 9,013 shares [2]. - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 8.1119 million shares, while Southern CSI 500 ETF reduced its holdings by 256,900 shares [3].

Core Viewpoint - Wanfu Biological experienced a stock price increase of 12.81% year-to-date, with a notable rise of 4.11% in the last five trading days, indicating positive market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Wanfu Biological reported a revenue of 1.69 billion yuan, a year-on-year decrease of 22.52%. The net profit attributable to shareholders was 134 million yuan, down 69.32% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.213 billion yuan, with 601 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wanfu Biological was 42,400, a decrease of 5.59% from the previous period. The average number of circulating shares per shareholder increased by 5.94% to 10,160 shares [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.1927 million shares, a reduction of 1.3623 million shares from the previous period. The Southern Zhongzheng 1000 ETF held 2.6442 million shares, down by 20,900 shares [3]. Business Overview - Wanfu Biological, established on November 13, 1992, and listed on June 30, 2015, specializes in the research, production, and sales of rapid diagnostic reagents and instruments related to point-of-care testing (POCT) [1]. - The company's revenue composition includes chronic disease testing (45.93%), infectious disease testing (30.93%), drug abuse testing (11.82%), pregnancy and reproductive health testing (11.27%), and other supplementary services (0.04%) [1]. Market Position - Wanfu Biological is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics. The company is associated with various concept sectors, including avian influenza drugs, assisted reproduction, anti-influenza, gene sequencing, and the pet economy [1].

Core Viewpoint - Wanfu Bio experienced a stock price decline of 2.03% on January 16, with a current price of 21.20 CNY per share and a market capitalization of 9.923 billion CNY [1] Group 1: Stock Performance - Year-to-date, Wanfu Bio's stock price has increased by 7.34%, with a 3.82% rise over the last five trading days and a 6.53% increase over the last 20 days, while it has decreased by 1.58% over the last 60 days [1] - As of September 30, the number of shareholders for Wanfu Bio is 42,400, a decrease of 5.59% from the previous period, with an average of 10,160 circulating shares per person, an increase of 5.94% [2] Group 2: Financial Performance - For the period from January to September 2025, Wanfu Bio reported a revenue of 1.690 billion CNY, a year-on-year decrease of 22.52%, and a net profit attributable to shareholders of 134 million CNY, down 69.32% year-on-year [2] - Since its A-share listing, Wanfu Bio has distributed a total of 1.213 billion CNY in dividends, with 601 million CNY distributed over the last three years [3] Group 3: Shareholder Composition - As of September 30, 2025, among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 8.1927 million shares, a decrease of 1.3623 million shares from the previous period, while Southern Zhongzheng 1000 ETF holds 2.6442 million shares, a decrease of 20,900 shares [3] - Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3] Group 4: Company Overview - Wanfu Bio, established on November 13, 1992, and listed on June 30, 2015, is located in Guangzhou, Guangdong Province, and specializes in the research, production, and sales of rapid diagnostic reagents and instruments related to POCT [1] - The company's main business revenue composition includes chronic disease testing (45.93%), infectious disease testing (30.93%), drug abuse testing (11.82%), pregnancy and reproductive health testing (11.27%), and other (0.04%) [1]

Core Viewpoint - The stock price of Pulaike has shown a positive trend with a year-to-date increase of 6.44%, reflecting a strong performance in the animal health sector [2] Group 1: Stock Performance - As of January 13, Pulaike's stock price rose by 2.00% to 13.23 CNY per share, with a trading volume of 46.33 million CNY and a turnover rate of 1.02% [1] - The stock has increased by 3.93% over the last five trading days and 2.40% over the last twenty days, while it has decreased by 4.68% over the last sixty days [2] Group 2: Company Overview - Pulaike Bioengineering Co., Ltd. was established on June 22, 2002, and went public on May 18, 2015. The company is primarily engaged in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2] - The revenue composition of Pulaike includes poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2] Group 3: Financial Performance - For the period from January to September 2025, Pulaike achieved an operating income of 823 million CNY, representing a year-on-year growth of 8.04%. The net profit attributable to shareholders was 157 million CNY, reflecting a significant increase of 47.86% [2] - Since its A-share listing, Pulaike has distributed a total of 1.125 billion CNY in dividends, with 568 million CNY distributed over the past three years [3] Group 4: Shareholder Information - As of September 30, 2025, Pulaike had 16,700 shareholders, a decrease of 7.26% from the previous period, with an average of 20,739 circulating shares per shareholder, an increase of 7.83% [2] - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranks as the sixth largest, holding 5.4716 million shares, an increase of 2.0217 million shares from the previous period [3]

Core Viewpoint - The stock price of Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has shown a positive trend, with a year-to-date increase of 7.38% and a recent uptick in trading activity, indicating potential investor interest and market confidence in the company's performance [2]. Group 1: Stock Performance - As of January 8, the stock price increased by 2.02%, reaching 10.62 CNY per share, with a trading volume of 1.11 billion CNY and a turnover rate of 0.88%, resulting in a total market capitalization of 12.732 billion CNY [1]. - The stock has experienced a 7.49% increase over the last five trading days and a 2.02% increase over the last 20 days [2]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 7.923 billion CNY, reflecting a year-on-year growth of 0.61%, while the net profit attributable to shareholders decreased by 10.55% to 461 million CNY [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.726 billion CNY, with 445 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 54,400, a rise of 5.04%, with an average of 22,041 circulating shares per shareholder, which is a decrease of 4.79% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 28.6504 million shares, an increase of 6.1171 million shares compared to the previous period [3].

Group 1 - The company Kelong Pharmaceutical announced a share buyback plan with a total amount between 50 million and 100 million yuan, at a maximum price of 35.00 yuan per share, funded by its own resources, within a 12-month period [1] - The current stock price of Kelong Pharmaceutical is 30.18 yuan, reflecting a year-to-date increase of 2.83%, with the proposed buyback price being 15.97% higher than the current price [1] - Kelong Pharmaceutical's main business includes the development, production, and sales of large-volume infusion products, with revenue composition being 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from R&D projects, and 3.33% from others [1] Group 2 - As of September 30, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period, while the average circulating shares per person decreased by 7.70% to 35,200 shares [2] - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] Group 3 - Kelong Pharmaceutical has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [3] - As of December 31, 2025, the top ten circulating shareholders include notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their shareholdings [3]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.01% on January 5, 2025, and a total market capitalization of 478.46 billion yuan [1] - As of January 5, 2025, the stock price is reported at 29.94 yuan per share, with a trading volume of 1.64 billion yuan and a turnover rate of 0.43% [1] - The company has experienced a year-to-date stock price increase of 2.01%, but has seen declines of 1.77% over the last five trading days, 12.20% over the last 20 days, and 16.68% over the last 60 days [1] Group 2 - For the period from January to September 2025, Kelun Pharmaceutical reported a revenue of 13.277 billion yuan, representing a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [2] Group 3 - As of September 30, 2025, the number of shareholders for Kelun Pharmaceutical increased to 37,100, marking an 8.35% rise from the previous period, while the average number of circulating shares per person decreased by 7.70% to 35,200 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings for several institutional investors, such as China Europe Medical Health Mixed Fund and Industrial Bank Frontier Medical Stock A [3]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.05% on December 31, reaching 29.42 yuan per share, and a total market capitalization of 47.015 billion yuan [1] - As of September 30, 2025, Kelun Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company has a diverse revenue structure, with 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - Kelun Pharmaceutical has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] - The number of shareholders increased to 37,100 as of September 30, 2025, reflecting an 8.35% rise, while the average number of circulating shares per person decreased by 7.70% to 35,200 shares [2] - Major shareholders include China Europe Medical Health Mixed A, holding 40.0624 million shares, and Hong Kong Central Clearing Limited, holding 34.728 million shares, both of which have seen a reduction in their holdings compared to the previous period [3]

Group 1 - The core viewpoint of the news highlights the recent stock performance and trading activity of Tai Long Pharmaceutical, showing a 2.13% increase in stock price to 6.70 CNY per share, with a total market capitalization of 3.845 billion CNY [1] - The company has seen a year-to-date stock price increase of 31.63%, but has experienced a decline of 2.33% over the last five trading days and 11.26% over the last twenty days [1] - Tai Long Pharmaceutical has been featured on the "Dragon and Tiger List" three times this year, with the most recent instance on December 10, where it recorded a net buy of -8.4516 million CNY [1] Group 2 - Tai Long Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The company's revenue composition includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of September 30, 2025, Tai Long Pharmaceutical reported a revenue of 1.187 billion CNY, a year-on-year decrease of 11.47%, and a net profit of 25.3255 million CNY, down 12.36% year-on-year [2] Group 3 - Tai Long Pharmaceutical has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.5307 million CNY distributed over the past three years [3] - As of September 30, 2025, the company had 40,400 shareholders, a decrease of 1.08% from the previous period, with an average of 14,190 circulating shares per shareholder, an increase of 1.09% [2][3] - Notable institutional holdings include Guangfa Pension Index A as the eighth largest shareholder with 2.9719 million shares, down by 264,000 shares, and Huatai-PineBridge CSI Traditional Chinese Medicine ETF as the ninth largest shareholder with 2.8616 million shares, marking a new entry [3]